I-T-Cell Lymphoma (CTCL) ye-Cutaneous i- lymphoma yolusu. I-CTCL ivela kwi- T-cell , uhlobo lwe-lymphocyte okanye i-white cell cell. I-CTCL ayisisifo esinye, kodwa iqela leemilphomas ezahlukeneyo ezichaphazela ulusu ngokuquka:
- Mycosis fungoides,
- Isifo seSezary,
- I-reticulum cell sarcoma yolusu, kwaye
- Inani lezinye izilwanyana ezingabonakaliyo.
I-lymphoma iquka i- lymph nodes .
Nangona kunjalo, iiseli ze-lymph okanye i-lymphocytes zikhona kuzo zonke izitho zomzimba. Ulusu luyindlela ebalulekileyo yokukhusela isistim somzimba, kwaye ezinye i-T-cell zifudukela kwesikhumba ukukhusela ekukhuselweni. Iiseli zomhlaza ze-T-cell lymphoma ezinqamlezileyo nazo ziyafudukela ekhumbeni. Uninzi lwezixhobo ze-CTCL zihlobene nezilonda, okanye ukulimala, zivelisa esikhumbeni.
I-T-cell i-lymphoma ibonisa iqela lezinto ezinqabileyo ze-Non-Hodgkin Lymphoma (NHL). I-CTCL iphendula malunga ne-1 kwi-40 yezigulane ze-NHL ezandululweyo.
Izinto zobungozi
I-CTCL ithintela amadoda ngokuqhelekileyo kunabesifazane. Abantu ngabanye abane-CTCL bavame ukuba ngama-50 okanye ama-60. Abantwana abachaphazelekayo. Kuye kwanda ukwanda kwenani labantu abachaphazelekayo yesikhumba se-lymphoma kule minyaka engama-3 edlulileyo.
Akukho nto eyaziwayo malunga nesizathu se-CTCL. Ngokungafani nezinye iindidi ze-lymphomas, akukho mhlobo kunye neentsholongwane eziyaziwayo.
Uphando luyaqhubeka ukuqinisekisa ukuba yintoni ebangela i-CTCL.
Iimpawu
Iimpawu zokuqala ze-lymphoma yesikhumba zibandakanya isikhumba esomileyo okanye esinamaqabunga, ukuxubha obomvu, nokubetha. Iimvumba ziqhelekile kwiindawo ezihlala zihlanganiswe ngeengubo. Abanye abantu banokuqala babone iibomvu ezibomvu okanye ezimnyama esikhumbeni. Lezi zimpawu azixhomekekanga kwi-lymphoma kwaye abaninzi abantu bahlala bephathwa ngeemeko zengqondo eziqhelekileyo ngaphambi kokuba i-lymphoma ikhunjulwe.
Njengoko eso sifo siyaqhubeka, iifomthi ezibomvu ziphakanyisiwe, Ezi zikhuni eziphakamileyo ziyaziwa njengeiplati. Iiplati ziyakutya emva koko zibe ziimvumba ezinobunzima. Kwizifo eziphambili, izilonda zingakhula ngaphezulu kwezi zilonda. I-CTCL ingasasazeka kwii-lymph nodes okanye kwezinye izitho. Uninzi lwabantu abane-CTCL baneempawu zesikhumba. Phantse iipesenti ezili-10 zeemeko zecala lokugqibela ziqhubela phambili ukuphuhlisa iingxaki ezinzulu.
Ukuxilongwa
I-biopsy yolusu iyadingeka ukuxilonga i-CTCL. Isampuli ye-biopsy iya kuhlolwa phantsi kwe-microscope ukufumanisa iiseli ze-lymphoma. Ezinye iimvavanyo ezibandakanya iimvavanyo zamanqaku e-lymphoma (i-immunohistochemistry) kunye namajeni e-lymphoma kufuneka afune uhlobo lwe-lymphoma. Iimvavanyo ze-CT okanye ezinye iimvavanyo zengcamango zingenziwa ukuba zifumane ubukhulu besifo.
Unyango
Unyango lwe-lymphoma yesikhumba ehluke kakhulu kwindlela enye i-lymphomas ephathwa ngayo. Isicwangciso sonyango sakho siya kuxhomekeka kumlinganiselo wokubandakanyeka kwesikhumba, uhlobo lwesilonda sesikhumba, kunye nokubandakanyeka kwamalungu okanye ezinye izitho zomzimba.
Zininzi iintlobo zonyango ezisetyenziswayo:
- Iimpawu ze-Chemotherapy ezisetyenziswe elukhumbeni
- Itherapy yonyango ye-electron ye-skin - uhlobo lwonyango lwamayeza
- I-Psoralen kunye ne-ultraviolet Imibala
- Imizila ye-ultraviolet B
- I-Bexarotene - zombini njengejel kunye namacwecwe
- UDenileukin Difitox
- I-intelon alpha
- I-Chemotherapy ngamagciwane okanye iipilisi
Ngokugqithisileyo, i-US Food and Drug Administration (i-FDA) ivunyiwe i-mechlorethamine gel (Valchlor) ekukhuselweni kwesikhumba ye-mycosis fungoides, uhlobo oluqhelekileyo lwe-CTCL. Ngaphambi kokuba kuvunywe, i-mechlorethamine yavunywa kuphela ukuba yonyango.
ILizwi
Iqela lase-European consensus labafundi lidibene kwaye lishicilele iingcebiso zabo kwonyango lweentlobo ezahlukileyo kunye neemeko ze-CTCL, ngokubhekiselele ukuba le ndlela yokwelapha ejoliswe ngesikhumba iyona ndlela iyona ndlela ifanelekileyo kwi-stage-mycosis fungoides, kwaye ezininzi izigulane ezine-mycosis fungoides zinokukhangela phambili kwixesha eliqhelekileyo lokuphila.
Ngelishwa, ukugxekwa akukabi kakuhle kwizigulane ezinezifo eziphambili, bathi, nangona i-subset ekhethiweyo kakhulu yezigulane, ukusinda ixesha elide kungenziwa nge-allogeneic stem cell transplantation (alloSCT).
Sekunjalo, kukho inkqubela eninzi kwiminyaka elishumi edlulileyo malunga nokuqonda indlela i-mycosis fungicides kunye ne-Sezary syndrome eqhubeka ngayo, ngoko kukho ithemba lokuba oku kuya kubangela unyango oluqhubekayo.
> Imithombo:
> Trautinger F, Eder J, Assaf C, et al. I-European Organisation for Research and Treatment of Cancer ingcebiso malunga nokunyangwa kwe-mycosis fungoides / i-Sezary syndrome - Uhlaziyo 2017. I- Eur J Cancer. 2017; 77: 57-74.